The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?
Open accessAbstract
Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies on pulmonary hypertension also show improvement in the 6-min walking distance (788).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [788]
Citations
Cites
1 retracted
Xu, J., Wu, Y., Song, P., Zhang, M., Wang, S., & Zou, M. (2007) · Circulation · doi:10.1161/circulationaha.106.684795 · Cited by 193
RetractedNitric oxide synthases: regulation and function
Forstermann, U., & Sessa, W. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr304 · Cited by 4,409
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity
Bray, G. A., Nielsen, S. J., & Popkin, B. M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.537 · Cited by 1,990
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo
Rees, D. D., Palmer, R. M. J., Schulz, R., Hodson, H. F., & Moncada, S. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb14151.x · Cited by 1,856
Protein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,810
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729 · cited 1×
“Combined daily administration of folic acid, vitamin B6, and vitamin B12 for five years had no beneficial effects on major vascular events in a high-risk population with vascular disease (Lonn et al., 2006).”
BackgroundJones, D. P. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1865 · Cited by 1,726
Cited by
Sorted by citations
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment
Matsuzawa, Y., & Lerman, A. (2014) · Coronary Artery Disease · doi:10.1097/mca.0000000000000178 · Cited by 249
Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms
Kankaanranta, H., Kauppi, P., Tuomisto, L. E., & Ilmarinen, P. (2016) · Mediators of Inflammation · doi:10.1155/2016/3690628 · Cited by 122
Villalba, N., Sackheim, A. M., Nunez, I. A., Hill-Eubanks, D. C., Nelson, M. T., Wellman, G. C., & Freeman, K. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2015.4340 · Cited by 99
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84
Metadata
- Authors
- Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C.
- Affiliations
- Université de Bourgogne (FR)
- Inserm (FR)
- Corresponding author
- Rochette, Luc
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 140
- Issue
- 3
- Pages
- 239-257
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2035714184
- Cited by
- 456
- References
- 201
- Citations by year
- 2026: 17 · 2025: 36 · 2024: 29 · 2023: 50 · 2022: 42 · 2021: 40 · 2020: 31 · 2019: 39 · 2018: 36 · 2017: 40 · 2016: 29 · 2015: 37 · 2014: 23 · 2013: 5
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
- ube.hal.science
- Licence
- other-oa
- Locations
- Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- nitric oxide synthase inhibition, nitric oxide, oxidative stress, cardiovascular disease, asymmetric dimethylarginine, tetrahydrobiopterin, endothelial dysfunction, endothelial nitric oxide synthase, NOS isoforms, calmodulin, hypertension, ischemia-reperfusion injury, diabetes mellitus, vascular dysfunction, therapeutic target
- MeSH terms
- Animals, Cardiovascular Diseases, Enzyme Inhibitors, Humans, Nitric Oxide, Oxidative Stress, Nitric Oxide Synthase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
